Ultragenyx Reports Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ultragenyx Pharma (RARE) Has Multiple Catalysts in 2015 - Jefferies
March 26, 2015 8:36 AM EDTJefferies analyst Ryan Martins reiterated a Buy rating and $74 price target on Ultragenyx Pharma (NASDAQ: RARE) noting multiple catalysts in 2015.
Martins commented, "All of RARE's clinical programs are on track, with either phase 2 data or initiation of pivotal trials planned in 2015. Key updates included... More
Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c
March 25, 2015 4:06 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.52), $0.01 better than the analyst estimate of ($0.53).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More